Dr. André presents a critical analysis of real-world evidence for MSI-H/dMMR colon cancer, focusing on the paradigm shift driven by immune checkpoint inhibitors. The presentation bridges clinical oncology and surgical integration, discussing long-term survival benefits observed in clinical practice. The session provides an in-depth review of key landmark studies and explores how these evidence-based results are effectively translated into current standard-of-care pathways for colorectal cancer patients.
Share it with your network and help spread clinical knowledge.
